CME

CAR T Therapy: From Bench to Bedside and Back


 

Disclaimer

The content and views presented in this educational activity are those of the author and do not necessarily reflect those of Hemedicus or Frontline Medical Communications. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.

Pages

Recommended Reading

Family engagement can buffer early cognitive hit from SCD
MDedge Hematology and Oncology
Sickle cell disease exacts a heavy vocational toll
MDedge Hematology and Oncology
Voxelotor cut transfusions in compassionate use sickle cell cohort
MDedge Hematology and Oncology
Hydroxyurea well tolerated in longitudinal European study
MDedge Hematology and Oncology
A new use for ibrutinib?
MDedge Hematology and Oncology
FDA lifts hold on trial of MYC inhibitor
MDedge Hematology and Oncology
Leading researcher in genetics, hematology dies at 84
MDedge Hematology and Oncology
Voxelotor benefits adolescents with SCD
MDedge Hematology and Oncology
Drug is convenient alternative for PNH, doc says
MDedge Hematology and Oncology
Mircera approved for anemia in pediatric patients with CKD
MDedge Hematology and Oncology